80 Guest Street
Suite 601
Boston, MA 02135
United States
617 500 8099
https://www.compasstherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 24
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, CEO & Director | 454k | N/A | 1961 |
Dr. Vered Bisker-Leib MBA, Ph.D. | Pres & COO | 720k | N/A | 1971 |
Dr. Susan Kalled Ph.D. | Chief Scientific Officer | 445.5k | N/A | 1961 |
Mr. Neil L. Lerner CPA | VP of Fin. | N/A | N/A | 1967 |
Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corp. Sec. | N/A | N/A | N/A |
Anna Gifford | Communications Mang. | N/A | N/A | N/A |
Dr. Peter F. Moesta Ph.D. | Interim Head of CMC | N/A | N/A | N/A |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.